Getting FDA approval for a new drug takes about 10 to 15 years from early research through clinical trials to a final decision, though the timeline varies widely depending on the type of product and the regulatory pathway used. For medical devices, the process can be as short as a few months. The specific phase of development, the severity of the disease being treated, and whether a product qualifies for expedited review all shape how long the journey takes.
The Full Drug Approval Timeline
The process of bringing a new drug to market has several distinct stages, each with its own clock. Before any human testing begins, a company spends years on preclinical research: identifying a promising compound, testing it in the lab, and running animal studies to assess safety. This phase alone can take three to six years, though the underlying science often stretches back much further. A study published in PLOS One found that the median time from the very first scientific discovery behind a drug to FDA approval was 36 years.
Once a company files an Investigational New Drug application and gets the green light to test in humans, the clinical trial process begins. The FDA breaks this into three phases:
- Phase 1 tests the drug in a small group of healthy volunteers to evaluate safety and dosing. This typically takes several months.
- Phase 2 expands testing to patients with the target condition, looking at both effectiveness and side effects. This runs several months to two years.
- Phase 3 involves large-scale trials with hundreds or thousands of patients to confirm the drug works and monitor adverse reactions. These trials last one to four years.
From the start of Phase 1 clinical trials to approval, the median time is about eight years. Only about 12.8% of drugs that enter clinical trials ultimately receive approval, meaning the vast majority fail along the way, most commonly during Phase 2 and Phase 3 when effectiveness is being tested.
How Long the FDA Review Itself Takes
After a company completes its clinical trials and submits a New Drug Application or Biologics License Application, the FDA’s own review clock starts. The agency first spends 60 days deciding whether to formally accept the application for review. From that filing date, the timeline depends on the review type.
Standard review has a goal of 10 months from the filing date. Priority review, reserved for drugs that offer significant improvements over existing treatments, has a goal of 6 months. These are performance targets the FDA commits to under an agreement with the pharmaceutical industry called PDUFA (Prescription Drug User Fee Act), and the agency hits these targets for 90% of applications.
Companies pay substantial fees to fund this review process. For fiscal year 2025, the application fee for a drug requiring clinical data is $4,310,002. Applications without clinical data cost $2,155,001. These fees help the FDA maintain the staffing needed to meet its review deadlines.
Expedited Pathways That Shorten the Process
The FDA offers four programs designed to speed things up for drugs that treat serious conditions. These can dramatically cut years off the development timeline.
Breakthrough therapy designation has the biggest impact. Drugs receiving this designation had a median development time of 4.8 years from clinical trials to approval, compared to 8.0 years for drugs without any expedited designation. The FDA provides intensive guidance throughout development, helping companies design more efficient trials. Fast track designation also shortens the process, bringing the median development time to about 7.0 years. Accelerated approval allows the FDA to approve drugs based on surrogate endpoints, like tumor shrinkage instead of long-term survival, which can eliminate years of follow-up study. Priority review compresses the FDA’s own review period from 10 months to 6.
These designations can be combined. A drug can receive both breakthrough therapy and priority review, stacking the time savings across both the clinical development and review phases.
Medical Device Timelines
Medical devices follow a completely different process, and the timelines are much shorter. The path depends on how much risk the device poses.
Most moderate-risk devices (Class II) go through what’s called 510(k) clearance, where a company demonstrates that its device is substantially equivalent to one already on the market. The FDA’s goal is to make a decision within 90 “FDA days,” which excludes time when the agency is waiting for the company to respond to questions. If the review stretches past 100 FDA days, the agency issues a formal communication explaining the delay and providing an estimated completion date.
High-risk devices (Class III), such as implantable heart valves or deep brain stimulators, require Premarket Approval. This is a much more rigorous process that typically includes clinical trial data. The FDA has 180 days from the filing date to complete its review. However, if the company submits significant new data during the review, the clock can reset for another 180 days. In practice, the back-and-forth between companies and the FDA means many PMA reviews extend well beyond the initial 180-day window.
Generic Drug Approval Times
Generic drugs skip most of the clinical trial process because the active ingredient has already been proven safe and effective. Instead, companies file an Abbreviated New Drug Application showing their version is bioequivalent to the brand-name drug.
Current FDA performance data shows generic drug approvals averaging about 35 to 42 months from submission to approval, though this varies by quarter. The most recent data from the FDA’s fiscal year 2025 tracking shows a quarterly mean of about 36 to 37 months. These timelines can be extended by patent disputes, manufacturing issues, or the need for additional bioequivalence studies.
What Happens After Approval
Approval doesn’t end the process. The FDA often requires Phase 4 post-marketing studies as a condition of approval. These studies track the drug’s performance in larger, more diverse populations over longer periods. They can focus on specific safety concerns, drug interactions, use in special populations like pregnant women or children, or long-term cancer risk. Phase 4 studies run for years or even decades after a drug reaches the market, and their findings can lead the FDA to add new warnings, restrict use, or in rare cases withdraw a drug entirely.